223 related articles for article (PubMed ID: 32901837)
1. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Xu D; Zhou Y; Xie X; He L; Ding J; Pang S; Shen B; Zhou C
Int J Oncol; 2020 Nov; 57(5):1223-1233. PubMed ID: 32901837
[TBL] [Abstract][Full Text] [Related]
2. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway.
Luo J; Sun P; Zhang X; Lin G; Xin Q; Niu Y; Chen Y; Xu N; Zhang Y; Xie W
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948132
[TBL] [Abstract][Full Text] [Related]
4. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
5. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT Signalling Pathway.
Fang K; Wang L; Chen L; Liu T; Fang Z
Med Sci Monit; 2019 Apr; 25():2943-2949. PubMed ID: 31005960
[TBL] [Abstract][Full Text] [Related]
8. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
9. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Qiu J; You L; Zheng L; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2018 Nov; 37(1):274. PubMed ID: 30419950
[TBL] [Abstract][Full Text] [Related]
10. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation.
Hung MH; Chen YL; Chen LJ; Chu PY; Hsieh FS; Tsai MH; Shih CT; Chao TI; Huang CY; Chen KF
Cell Death Dis; 2019 May; 10(6):420. PubMed ID: 31142735
[TBL] [Abstract][Full Text] [Related]
12. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Li J; Liang X; Yang X
Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480
[TBL] [Abstract][Full Text] [Related]
13. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction.
Jia L; Huang S; Yin X; Zan Y; Guo Y; Han L
Life Sci; 2018 Sep; 208():123-130. PubMed ID: 30025823
[TBL] [Abstract][Full Text] [Related]
14. PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway.
Pan Y; Rhea P; Tan L; Cartwright C; Lee HJ; Ravoori MK; Addington C; Gagea M; Kundra V; Kim SJ; Newman RA; Yang P
Invest New Drugs; 2015 Apr; 33(2):271-9. PubMed ID: 25476893
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K/AKT/GSK-3β/mTOR and Wnt/β-catenin pathways;
Abdel-Rafei MK; Thabet NM; Rashed LA; Moustafa EM
J Cancer Res Ther; 2021; 17(6):1404-1418. PubMed ID: 34916371
[TBL] [Abstract][Full Text] [Related]
16. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway.
Boreddy SR; Pramanik KC; Srivastava SK
Clin Cancer Res; 2011 Apr; 17(7):1784-95. PubMed ID: 21350002
[TBL] [Abstract][Full Text] [Related]
19. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
[TBL] [Abstract][Full Text] [Related]
20. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]